NCT03247972View on ClinicalTrials.gov

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

TerminatedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

August 11, 2017

Primary Completion Date

September 1, 2019

Study Completion Date

October 1, 2019

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Evolocumab

Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.

Trial Locations (1)

22042

Inova Fairfax Hospital, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER